© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
December 05, 2012
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.
March 04, 2011
Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.
Joseph Goldberg, MD: Treating Mixed Feature Depression
M. Katherine Shear, MD: Addressing Grief After a Loss
Larry Culpepper, MD: The Challenge of Treating BPD